Product Description
please call me , to know more
AI Product Description
*The following content is generated by AI and is for reference only.
Sofosbuvir, marketed under the brand name Sovaldi, is a pioneering nucleotide analog prodrug developed by Gilead Sciences for the treatment of chronic hepatitis C virus (HCV) infection. With the Chemical Abstracts Service (CAS) registry number 850164-23-9, this compound represents a significant milestone in antiviral therapy due to its high efficacy and favorable safety profile. The molecular formula of Sofosbuvir is C22H29FN6O9P, reflecting its complex structure designed to mimic natural nucleotides within the viral replication machinery.
The primary mechanism of action involves the intracellular conversion of Sofosbuvir into its active triphosphate metabolite. This active form competitively inhibits the HCV RNA-dependent RNA polymerase, specifically the NS5B protein, thereby halting viral RNA synthesis and preventing the virus from replicating. Unlike older interferon-based regimens, Sofosbuvir targets the virus directly without requiring immune modulation, making it suitable for patients with compromised liver function or those who have failed previous treatments. It is typically administered as a single daily oral tablet, often in combination with other direct-acting antivirals such as ledipasvir, velpatasvir, or ribavirin, depending on the specific HCV genotype and patient history.
Clinical trials have demonstrated cure rates exceeding 95% across various genotypes, including difficult-to-treat strains like genotype 3. Its approval marked a paradigm shift in hepatology, moving away from lengthy, side-effect-heavy therapies toward short, well-tolerated courses lasting eight to twelve weeks. While generally well-tolerated, common side effects may include fatigue, headache, and nausea. As a cornerstone of modern HCV management, Sofosbuvir has played a crucial role in global efforts to eliminate hepatitis C as a public health threat, significantly reducing transmission rates and associated complications like cirrhosis and hepatocellular carcinoma. Its introduction has set new standards for drug development in the field of antiviral pharmacology, emphasizing precision targeting and patient-centric outcomes.